These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7583915)

  • 1. Reversal of immunosuppression of lymphocyte proliferation caused by sera from persons with AIDS.
    Tomar RH; John P; Hinds P
    Clin Diagn Lab Immunol; 1995 Jul; 2(4):408-11. PubMed ID: 7583915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy.
    Ascherl G; Hohenadl C; Schatz O; Shumay E; Bogner J; Eckhart L; Tschachler E; Monini P; Ensoli B; Stürzl M
    Blood; 1999 Jun; 93(12):4232-41. PubMed ID: 10361120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes.
    Siegel JP; Djeu JY; Stocks NI; Masur H; Gelmann EP; Quinnan GV
    J Clin Invest; 1985 Jun; 75(6):1957-64. PubMed ID: 2989337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera.
    Hofmann B; Langhoff E; Lindhardt BO; Odum N; Hyldig-Nielsen JJ; Ryder LP; Platz P; Jakobsen BK; Bendtzen K; Jacobsen N
    Cell Immunol; 1989 Jul; 121(2):336-48. PubMed ID: 2786762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of interleukin-2-induced T-cell proliferation by sera from patients with the acquired immune deficiency syndrome.
    Donnelly RP; Tsang KY; Galbraith GM; Wallace JI
    J Clin Immunol; 1986 Jan; 6(1):92-101. PubMed ID: 3007564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of in vitro lymphocyte proliferation by serum from acquired immune deficiency syndrome patients depends on the ratio of cells to serum in culture.
    Hennig AK; Tomar RH
    Clin Immunol Immunopathol; 1984 Nov; 33(2):258-67. PubMed ID: 6488591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sera from AIDS patients inhibit the responsiveness of normal lymphocytes in allogeneic and autologous mixed lymphocyte cultures.
    Puppo F; Stagnaro R; Ruzzenenti R; Indiveri F
    Allergol Immunopathol (Madr); 1991; 19(2):89-94. PubMed ID: 1837701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum antibodies to HIV-1 are produced post-measles virus infection: evidence for cross-reactivity with HLA.
    Baskar PV; Collins GD; Dorsey-Cooper BA; Pyle RS; Nagel JE; Dwyer D; Dunston G; Johnson CE; Kendig N; Israel E; Nalin DR; Adler WH
    Clin Exp Immunol; 1998 Feb; 111(2):251-6. PubMed ID: 9486389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody specificity for human immunodeficiency virus type 1 in serum and cerebrospinal fluid from patients with AIDS and AIDS-related complex.
    Willoughby PB; Midgett JS; Folds JD
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1031-7. PubMed ID: 2482809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble suppressor factors in patients with acquired immune deficiency syndrome and its prodrome. Elaboration in vitro by T lymphocyte-adherent cell interactions.
    Laurence J; Gottlieb AB; Kunkel HG
    J Clin Invest; 1983 Dec; 72(6):2072-81. PubMed ID: 6605980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral-mediated suppression of interleukin 2-dependent target cell proliferation in acquired immune deficiency syndrome (AIDS): interference with normal IL-2 receptor expression.
    Donnelly RP; La Via MF; Tsang KY
    Clin Exp Immunol; 1987 Jun; 68(3):488-99. PubMed ID: 3115647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells.
    Katz JD; Nishanian P; Mitsuyasu R; Bonavida B
    J Clin Immunol; 1988 Nov; 8(6):453-8. PubMed ID: 2975670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.
    Sei Y; Tsang PH; Roboz JP; Sarin PS; Wallace JI; Bekesi JG
    J Clin Immunol; 1988 Nov; 8(6):464-72. PubMed ID: 3146584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial purification and identification of an immunosuppressive factor in AIDS sera.
    Oh SK; Cerda S; Lee BG; Blanchard GC; Walker JE; Hartshorn K
    AIDS Res Hum Retroviruses; 1993 Apr; 9(4):365-73. PubMed ID: 7685613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus neutralizing antibodies at different stages of the HIV disease: increased levels after azidothymidine treatment.
    Schmidtmayerová H; Lackovicová M; Stanková M; Brůcková M; Surový I; Ujhelyi E; Füst G; Mayer V
    Acta Virol; 1992 Mar; 36(2):157-65. PubMed ID: 1359767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells.
    Santoli D; Tweardy DJ; Ferrero D; Kreider BL; Rovera G
    J Exp Med; 1986 Jan; 163(1):18-40. PubMed ID: 2416868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.
    Sawyer LA; Katzenstein DA; Hendry RM; Boone EJ; Vujcic LK; Williams CC; Zeger SL; Saah AJ; Rinaldo CR; Phair JP
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):341-56. PubMed ID: 1971182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.
    Ghetie V; Slaughter C; Wheeler HT; Uhr JW; Vitetta ES
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5690-3. PubMed ID: 2062847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.